the Tobacco group, Philip Morris International, said it had got 22.61% of the respiratory drug developer Vectura in a market purchase based in the U.K.
the Tobacco group, Philip Morris International, said it had got 22.61% of the respiratory drug developer Vectura in a market purchase based in the U.K.
Subscribe
Fill the form our team will contact you
Advertise with us
Fill the form our team will contact you
Leave us a message
Leave a Reply